A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia
Authors:
- 20 October 2011
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 13 (11) , 602-610
Abstract
Background: The purpose of the present phase I clinical trial was to evaluate the safety, tolerability, and preliminary efficacy of naked DNA therapy expressing two isoforms of hepatocyte growth factor (pCK‐HGF‐X7) in critical limb ischemia (CLI) patients.Materials and methods: Twenty‐one patients with CLI were consecutively assigned to receive increasing doses (cohort I: 4 mg; cohort II: 8 mg; cohort III: 12 mg; and cohort IV: 16 mg) of pCK‐HGF‐X7, which was administered into the ischemic calf and/or thigh muscle at days 1 and 15. A safety and tolerability evaluation and measurement of pain severity score using a visual analog scale (VAS), ulcer status, transcutaneous oxygen (TcPO2) and ankle‐brachial index (ABI) were performed throughout a 3‐month follow‐up period.Results: No serious adverse events were observed in any of the 21 patients for the 3‐month follow‐up period. A significant reduction in pain was observed in the treated patients, with the mean VAS decreasing from 5.95–1.64 (p < 0.001). The mean ABI value increased from 0.49–0.63 (p = 0.026) at 3‐month follow‐up. The mean TcPO2 value on the dorsum of the foot, the anterior calf and posterior calf significantly increased from 28.25–39.28 mmHg (p = 0.012), from 22.00–30.63 mmHg (p = 0.046) and 32.05–47.19 mmHg (p = 0.001) at 3‐month follow‐up, respectively. Wound healing improvement was observed in the six of nine patients that had an ulcer at baseline.Conclusions: These results support the performance of a phase II randomized controlled trial with pCK‐HGF‐X7. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 30 references indexed in Scilit:
- Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemiaJournal of Vascular Surgery, 2008
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- Critical Limb Ischemia and Stem Cell ResearchCirculation, 2006
- Hepatocyte growth factor as potential cardiovascular therapyExpert Review of Cardiovascular Therapy, 2005
- Induction of Angiogenesis and Inhibition of Apoptosis by Hepatocyte Growth Factor Effectively Treats Postischemic Heart FailureJournal of Cardiac Surgery, 2005
- Prevalence of and Risk Factors for Peripheral Arterial Disease in the United StatesCirculation, 2004
- Hepatocyte Growth Factor as Cardiovascular Hormone: Role of HGF in the Pathogenesis of Cardiovascular DiseaseEndocrine Journal, 2002
- Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Induces Vascular Permeability Factor (VPF/VEGF) Expression by Cultured KeratinocytesJournal of Investigative Dermatology, 1998
- Emerging Multipotent Aspects of Hepatocyte Growth FactorThe Journal of Biochemistry, 1996
- Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.Journal of Cell Biology, 1992